Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006392 · ClinicalTrials.gov registry record · Phase 3

S0000 Selenium and Vitamin E in Preventing Prostate Cancer

A Phase 3 study of Prostate Cancer, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 3
Development phase
35,533
Enrollment target
13
Study locations

NCT00006392 is a Phase 3 study of Prostate Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 35,533 participants, above the 560-participant average among 735 other Prostate Cancer trials with a reported enrollment target (6245% higher). The trial reports 13 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006392, a Phase 3 study of Prostate Cancer, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 3
Development phase
35,533 participants
Enrollment target
13
Study locations

Study Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Vitamin E
  • DRUG Selenium
  • OTHER Vitamin E placebo
  • OTHER selenium placebo

Study Locations (13)

Illinois

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
  • Midwest Center for Hematology/Oncology - Joliet
  • Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood

Ohio

  • Good Samaritan Hospital Cancer Treatment Center - Cincinnati
  • Bethesda North Hospital - Cincinnati
  • Tod Children's Hospital - Youngstown

Pennsylvania

  • Geisinger Medical Center - Danville
  • Geisinger Medical Group - Scenery Park - State College
  • Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center - Wilkes-Barre

Missouri

  • CCOP - Cancer Research for the Ozarks - Springfield
  • St. John's Regional Health Center - Springfield

Oklahoma

  • LaFortune Cancer Center at St. John Medical Center - Tulsa

Tennessee

  • U.T. Cancer Institute at University of Tennessee Medical Center - Knoxville

Trial Details

FieldValue
Enrollment Target 35,533 participants
Start Date 2001-07
Est. Completion 2012-09
Phase Phase 3

Sponsor

SWOG Cancer Research Network

270 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00006392

The ClinicalTrials.gov registry entry for NCT00006392 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 35,533 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 560-participant average among 735 other Prostate Cancer trials with a reported enrollment target (6245% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Vitamin E is the first listed.

NCT00006392 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00006392 about?

NCT00006392 is a clinical study titled "S0000 Selenium and Vitamin E in Preventing Prostate Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of selen...

What is the current status of trial NCT00006392?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 35,533 participants. The study started on 2001-07. Estimated completion is 2012-09.

What conditions does trial NCT00006392 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00006392?

The interventions under investigation include: Vitamin E (DRUG), Selenium (DRUG), Vitamin E placebo (OTHER), selenium placebo (OTHER).

Who is sponsoring clinical trial NCT00006392?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006392 being conducted?

This trial has 13 study locations across Illinois, Missouri, Ohio, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.